Two oral GLP-1 medicines for obesity are moving through late-stage testing, but neither is available in pharmacies yet. On Friday, August 14, 2026, two developments were tracked: one trial has finished collecting data, and another is still enrolling and following participants. For readers hoping for a pill alternative to injections, this distinction matters. Completion of a trial is a step forward, but it does not mean the drug is approved or on shelves.
A Phase 3 trial of the oral semaglutide pill for obesity in East Asian adults has finished, which means researchers have stopped collecting new data from participants. This is a meaningful milestone, but it is only the first half of the process. The results of this trial, which would show how well the pill worked and what side effects appeared, have not been published yet. Until that data is released and reviewed, no one outside the study team knows whether this pill performed well enough in East Asian adults to support approval for that population. If you are waiting on this specific trial because you fall into that demographic group, the honest answer right now is that there is nothing new to act on yet.
Eli Lilly's once-daily obesity pill, orforglipron, remains in a large Phase 3 trial that is now listed as active but not recruiting. That status means the study already has all the participants it needs, and it is now following them over time rather than signing up new people. This is a normal and expected phase for a trial this size, and it does not signal a problem. It does mean, however, that orforglipron is not something a patient can currently obtain outside of this study. Anyone interested in this pill should expect the timeline to run in months, not weeks, before more information becomes public.
If you are tracking either of these pills as a future treatment option, the most useful thing you can do right now is wait for published results rather than rely on speculation. Two practical steps can help in the meantime. First, ask your prescriber what current, already approved GLP-1 options exist for your situation, since those decisions do not need to wait on pipeline drugs. Second, check back on these specific trial records periodically, since status updates like a completed trial or newly posted results will appear there before they show up anywhere else.
Key details
A Phase 3 trial of the oral semaglutide pill for obesity in East Asian adults has…
Eli Lilly's once-daily obesity pill orforglipron remains in a large Phase 3 trial that…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-14